Skip to main content

Table 3 Viral nucleic acid negative-conversion within 14 days and not negative rate at last assay in different treatment groups

From: Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID‐19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series

Feature Without Arbidol (n = 63)a With Arbidol (n = 99) p value OR (95% CI)
Time to PCR negative in respiratory specimens
 ≤ 14 days (%) 35 (55.6) 72 (72.7) 0.028* 0.47 (0.24, 0.91)
 > 14 days (%) 28 (44.4) 27 (27.3) 0.028*  
 Not negative (%) 9 (14.3) 5 (5.1) 0.049* 3.13 (1.00, 9.83)
  Control (n = 32) Other antiviral drugs (n = 31) Arbidol only (n = 69) Arbidol + other antiviral drugs (n = 30)
 ≤ 14 days (%) 14 (43.8) 21 (67.7) 53 (76.8)*b 19 (63.3)
 > 14 days (%) 18 (56.2) 10 (32.3) 16 (23.2) 11 (36.7)
Not negative (%) 6 (18.8) 3 (9.7) 5 (7.2) 0 (0.00)
  1. *Statistically significant p vaues
  2. aA minority of patients didn't accept nucleic acid detection after hospitalization
  3. bControl group versus Arbidol group: OR = 0.23, 95% CI 0.10–0.57, p = 0.002